CSS
JANX icon

Cubist Systematic Strategies’s Janux Therapeutics JANX Stock Holding History

Cubist Systematic Strategies’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$6.29M Buy
257,527
+115,751
+82% +$2.82M 0.03% 825
2025
Q2 		$3.28M Buy
141,776
+65,916
+87% +$1.74M 0.02% 1280
2025
Q1 		$2.05M Buy
75,860
+35,511
+88% +$1.34M 0.01% 1404
2024
Q4 		$2.16M Buy
+40,349
New +$2.13M 0.01% 1305
2024
Q2 		– Sell
-6,808
Closed -$256K – 3490
2024
Q1 		$256K Buy
+6,808
New +$148K ﹤0.01% 2957

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cubist Systematic Strategies's JANX Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Janux Therapeutics (JANX) stake by 82% in Q3 2025, buying an estimated $2.82M and bringing the position to 257,527 shares worth $6.29M. The position accounts for 0.03% of the portfolio, ranked #825.

Cubist Systematic Strategies first reported a position in JANX in Q1 2024 and has held it in 5 quarters since. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

  • Cubist Systematic Strategies held 257,527 shares of Janux Therapeutics worth $6.29M as of Q3 2025.
  • Cubist Systematic Strategies bought 115,751 Janux Therapeutics shares in Q3 2025, an estimated $2.82M.
  • Janux Therapeutics made up 0.03% of Cubist Systematic Strategies's portfolio in Q3 2025, its #825 holding.
  • Cubist Systematic Strategies first reported a position in Janux Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.